View clinical trials related to Dialysis; Complications.
Filter by:This research is being done to better understand the impact of the use of a specific physical activity training program (GH Method) in dialysis/kidney disease patients.
This prospective, multicenter, cross-sectional, repeated-measures comparative study compared functional and biochemical response profiles to exercise between 2 groups of chronically ill patients (chronic renal failure dialysis patients and patients with metabolic syndrome) and a group of healthy subjects. The hypothesis is that the addition of plasma metabolic intermediates associated with energy disorders linked to insulin resistance, will improve the sensitivity of the assessment of muscle oxidative metabolism abnormalities, as reported in exercise intolerant subjects. In this way, the metabolomics approach during exercise would provide a biological and functional "signature" of insulin resistance of muscular origin, discriminating between insulin-resistant patients, healthy control subjects and dialysis patients, with an exercise metabolic profile approaching that observed in insulin-resistant patients. A better understanding of metabolic abnormalities could guide muscle rehabilitation. Participants will be asked to perform an exercise test, with several blood samples taken at different exercise intensities. Researchers will compare the metabolic profile of three groups: patients with chronic kidney disease, patients with metabolic syndrome and healthy subjects: - V'O2-adjusted lactate at rest and during exercise - The combination of exercise energy metabolism intermediates reflecting insulin resistance among Krebs cycle cofactors/substrates, ß-oxidation cofactors/substrates, amino acids
This study is a multicenter, prospective and randomized controlled study. The experiment includes a 1-week screening period (1 week before dialysis) and a 7-week treatment period (1-4 weeks of dose drip period and 5-7 weeks of evaluation period). During the screening period, all patients were randomly divided into the control group and the treatment group. On the non-dialysis day of the treatment period, the treatment group was given a certain dose of sodium zirconium silicate, and the blood potassium value was measured before and after each dialysis to maintain the blood potassium at 4.0-5.0mmol/L before dialysis. At the same time, 12-lead ECG and 24-hour Holter were completed at the first and last dialysis during the treatment period, and finally the ECG stability and its relationship with blood potassium were evaluated.
The aim of this study is to evaluate the effects of sodium and UF profiling on hemodynamic stability, interdialytic weight gain, and intradialytic complications
Patients performing chronic hemodialysis (HD) retain more or less water between dialyses. The water is removed by ultrafiltration and usually during the cleansing of waste products - the HD. The length of HD is usually the same as the time of fluid removal while sometimes this may differ. There is no clear guideline. In previous research the investigator noted that the heart releases more NT-pro-BNP during HD in numerous of the patients. The present study aims to clarify if the speed of fluid removal during HD is a factor that may alter the release of cardiac markers during HD. If so the recommendations for the prescription of HD can be updated.
As Korea is becoming a super-aged society, the number of elderly patients with end-stage kidney disease (ESKD) is expected to increase rapidly. Therefore, the burden on Korean society will also increase. Thrice-weekly hemodialysis is standard for renal replacement therapy. However, this regimen has not been validated for elderly ESKD patients with residual renal function. Elderly patients can have multiple comorbidities such as hypertension, diabetes, cardiovascular disease, and impaired physical activity. Frequent hemodialysis could provoke falls, hypotension, and cognitive impairment. Previous reports have suggested the potential benefit of twice-weekly hemodialysis with incremental increases in frequency when residual renal function decreases. In addition, twice-weekly hemodialysis decreases hospitalization rates in frail patients. Therefore, the investigators hypothesized initiating renal replacement therapy with twice-weekly hemodialysis decreases the hopsitalizatoin rates compared with conventional thrice-weekly hemodialysis in elderly ESRD patients with residual renal function. This study is a pragmatic randomized clinical trial, multicenter study. Study subjects are incident ESRD patients (>= 60 years old, n=428) with residual urine volume ( > 500 mL/day) and follow up up to 2 years. Twice-weekly hemodialysis could be incremented according to clinical situations such as volume overload, hyperkalemia and uremic symptom. Primary outcome of this study is hospitalization rate during follow-up. Secondary outcomes include dialysis related hospitalization rate, the length of hospital stay, complication of dialysis,mortality rate and assessments of quality of life, frailty, and cost-utility.
The aim of this study is to investigate the factors affecting hemodialysis-associated fatigue and their impact on the physical and emotional well-being of patients. By identifying these factors, Investigators can develop effective strategies to reduce fatigue and enhance the overall quality of life for hemodialysis patients.
Exit site infection (ESI) is one of the major predisposing factors to peritoneal dialysis (PD) related peritonitis. Chlorhexidine Gluconate (CHG) has been widely used for cutaneous disinfection for half a century. TegadermTM CHG is a water-proof dressing with gel pads that provide 2% CHG to the skin surface and effectively prevents catheter-related infections for intravascular catheters. However, its use has not been accessed in patients with PD catheters. We aim to evaluate the effectiveness of TegadermTM CHG dressing in preventing ESI in PD patients.
The aim of the research study is to look at a new type of MRI scanning that can measure the amount of sodium in different parts of the body. Sodium (or 'salt') levels are very important in maintaining health, and high levels lead to high blood pressure. This is very important to patients with kidney disease, as the kidney is the main organ that regulates the amount of sodium in the body. It is possible to measure blood sodium levels, but this does not tell us how much sodium is present in other areas of the body. Previously, it has not been possible measure this. Sodium MRI (Na-MRI) is a new type of MRI scanning that can directly measure sodium in other parts of body such as skin, muscles, kidneys, and brain. The investigators believe that this will help to guide treatment in patients with kidney disease who are on haemodialysis, research studies are needed to prove the benefits.
Many symptoms such as fatigue, muscle cramps, dry mouth, and headache that develop in patients due to the hemodialysis treatment process affect the quality of life and comfort of people. Sujok therapy is an effective method in symptom management. Although sujok therapy is an uncomplicated acupressure, it has positive features such as being uncomplicated so that it can be applied by the patients themselves. This study is planned as a single-blind placebo-controlled randomized trial. Research Hypotheses H0/1: Hydrotherapy has no effect on symptom burden in hemodialysis patients. H0/2: Hydrotherapy has no effect on hemodialysis comfort in hemodialysis patients. H1/1: Hydrotherapy has an effect on symptom burden in hemodialysis patients. H1/2: Hydrotherapy has an effect on hemodialysis comfort in hemodialysis patients. Inclusion criteria of volunteers 1. 18 years or older 2. To be on HD treatment for at least 6 months In our study, there are three groups as experimental, placebo and control groups. Group application steps to be applied water jok therapy(experimental groups); The right foot in men and the left foot in women will be preferred, and the outer and inner surface of the foot will be massaged with a massage stick for an average of 3 minutes, then the middle of the area between the 3rd and 4th toes and the wrist line on the outer surface of the foot, which represents the kidney area in the macro system. The pain point will be determined with a diagnostic metal rod in the thoracic 12th spine and the area representing the lumbar 3rd spine region, and it will be fixed with the help of a Mexican bean seed patch in the appropriate size for the painful spot, and it will be ensured to remain in the area for at least 8 hours. Group administration steps to be administered placebo ( Placebo Groups); It is planned that all the application steps will be the same as the group in which water jok therapy was applied, but instead of Mexican bean seeds, the use of red plastic number bean, which is used to improve the counting skill, is planned. Control group application steps; It is planned to implement routine interventions applied in dialysis centers. Sujok therapy and placebo application will be applied by the researcher during each dialysis session and it is planned to be carried out in a way to complete 14 sessions. In the study, it is planned to use Dialysis Symptom Index together with Hemodialysis Comfort Scale Version Ⅱ for the groups before the application, after the seventh and fourteenth application.